Non-small Cell Lung Cancer (NSCLC) Clinical Trial
— STEREOOfficial title:
STEREOtactic Radiation and Adjuvant Chemotherapy in Lung Cancer (STEREO)
Verified date | March 2018 |
Source | University of Louisville |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial will test the feasibility of adjuvant chemotherapy after stereotactic body radiation therapy for early stage non-small cell lung cancer (NSCLC).
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | February 2015 |
Est. primary completion date | February 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age = 18 years - Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - Histologically diagnosed non-small cell lung cancer(NSCLC, cT1-T3 (<= 5cm) (AJCC 7ed). The following histologies are eligible: squamous cell carcinoma, adenocarcinoma, large cell carcinoma, large cell neuroendocrine, or non-small cell carcinoma not otherwise specified; bronchioloalveolar cell carcinoma is a subtype of NSCLC but will be excluded from this study because assessment of multifocal disease spread through the airways is difficult. - Required CT of the chest and abdomen with contrast unless medically contraindicated (evaluating both lungs, mediastinum, liver, and adrenals) and Whole Body Positron Emission Tomography (PET) for staging. An integrated PET/Computed Tomography (CT) will meet the CT and PET requirements for staging. Images must be read by a trained radiologist and performed 8 weeks prior to initiation of treatment. PET imaging must allow adequate visualization of the primary tumor, draining lymphatics in hilar and mediastinum, adrenals, and skeleton. Note: Per Radiation Therapy Oncology Group (RTOG) 0915 inclusion criteria, patients with hilar or mediastinal lymph nodes = 1cm and no abnormal hilar or mediastinal uptake on PET will be considered N0. Patients with > 1 cm hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but non-diagnostic uptake) may still be eligible if directed tissue biopsy of all abnormally identified areas are negative for cancer. - Deemed medically inoperable by an experienced thoracic cancer clinician for a standard lobectomy and lymph node sampling/dissection. Inoperability may be defined utilizing a number of criteria. These include any of the following: - Pretreatment Forced Expiratory Volume (FEV1) < 40% predicted - Postoperative FEV1 < 30% predicted - Severely reduced diffusion capacity - Baseline hypoxemia and/or hypercapnia - Exercise oxygen consumption < 50% predicted - Severe pulmonary hypertension - Diabetes mellitus with severe end organ damage - Severe cerebral, cardiac, or peripheral vascular disease - Decline surgery after evaluation by a thoracic surgeon Required laboratory values within 2 weeks of chemotherapy initiation - Absolute neutrophil count (ANC) = 1500 mm3 - Platelets = 100,000/mm3 - Total Bilirubin = 1.5 mg/dL - Serum glutamic oxaloacetic transaminase (SGOT)- aspartate aminotransferase (AST) < 5 x upper limit of normal (ULN} - Serum glutamic pyruvic transaminase (SGPT)- alanine transaminase(ALT) < 5 x upper limit of normal (ULN) - Serum Creatinine = 1.5 x institutional upper limit of normal (ULN) - For patients assigned to pemetrexed/Cisplatin therapy calculated Creatinine Clearance (CrCl) must be obtained within 2 weeks of randomization and calculated CrCl must be > 45mL/min using the standard Cockcroft and Gault formula Exclusion Criteria: - Primary lesion size not within the acceptable criteria - Evidence of regional metastases or distant metastases following appropriate staging - Previous radiation to the chest - Chemotherapy within the previous five years - Previous surgery for this particular lung tumor - Plans for concomitant chemotherapy with radiation - Active systemic or pulmonary infection - Pregnant or lactating females - Synchronous primary malignancy or prior malignancy in the past 2 years except for invasive malignancy that has been treated definitively and the patient remains disease free for > 3 years with life expectancy > 3 years. Previous skin cancers and carcinoma in situ treated definitively are acceptable. - Patients assigned to pemetrexed/cisplatin therapy must NOT have squamous cell histology - Bronchioloalveolar cell carcinoma is excluded because assessment of multifocal disease spread through the airways is difficult - Receipt of any other investigational agents or participation in any other investigational drug study within 4 weeks preceding initiation of study treatment |
Country | Name | City | State |
---|---|---|---|
United States | James Graham Brown Cancer Center | Louisville | Kentucky |
Lead Sponsor | Collaborator |
---|---|
University of Louisville | James Graham Brown Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To measure the feasibility of adjuvant chemotherapy after stereotactic body radiation therapy for early stage non-small cell lung cancer (NSCLC) | 3 years after subject enrollment | ||
Secondary | Survival rate, specifically disease-free survival (DFS) and overall survival (OS), measured by follow-up visits and tests | 3 years after subject enrollment | ||
Secondary | safety of adjuvant chemotherapy after stereotactic body radiation therapy for early stage non-small cell lung cancer (NSCLC) measured by adverse events | 3 years after subject enrollment | ||
Secondary | quality of life (QOL) measured by subject questionnaires | 3 years after subject enrollment | ||
Secondary | Measurement of biological and clinical markers for toxicity, DFS, and OS | 3 years after subject enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06040541 -
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT03667820 -
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
|
Phase 2 | |
Completed |
NCT02025114 -
Selumetinib in Combination With Gefitinib in NSCLC Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT01994057 -
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
|
||
Completed |
NCT01438307 -
Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01193959 -
Pemetrexed in Advanced Non-small Cell Lung Cancer
|
||
Recruiting |
NCT01028729 -
A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)
|
Phase 4 | |
Completed |
NCT00770588 -
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
|
Phase 4 | |
Active, not recruiting |
NCT05462717 -
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
|
Phase 1 | |
Completed |
NCT01951157 -
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
|
Phase 2 | |
Recruiting |
NCT01964157 -
An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
|
Phase 2 | |
Active, not recruiting |
NCT04026412 -
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
|
Phase 3 | |
Recruiting |
NCT05585320 -
A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03260491 -
HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT05207423 -
A Chart Review Study of Adults With Advanced NSCLC
|
||
Terminated |
NCT02608528 -
Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
|
||
Completed |
NCT01463423 -
Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)
|
N/A | |
Recruiting |
NCT02927340 -
A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
|
Phase 2 | |
Recruiting |
NCT02521051 -
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 |